

Imatinib and its combination with 2,5-dimethyl-celecoxib induces apoptosis of human HT-29 colorectal cancer cells

Somayeh Atari-Hajipirloo¹, Saba Nikanfar², Amir Heydari³, and Fatemeh Kheradmand^{4,*}

¹Department of Biochemistry, Student Research Committee, Urmia University of Medical Sciences, Urmia, I.R. Iran.

²Department of Biochemistry, Urmia University of Medical Sciences, Urmia, I.R. Iran.

³Department of Pharmacology, Cellular and Molecular Research Center, Urmia University of Medical Sciences, Urmia, I.R. Iran.

⁴Department of Clinical Biochemistry, Cellular and Molecular and Solid Tumor Research Center, Urmia University of Medical Sciences, Urmia, I.R. Iran.

Abstract

Mono-targeting by imatinib as a main antitumor agent does not always accomplish complete cancer suppression. 2,5-dimethyl-celecoxib (DMC) is a close structural analog of the selective cyclooxygenase-2 (COX-2) inhibitor, celecoxib, that lacks COX-2 inhibitory function. In this study, we aimed to show the apoptotic effects of imatinib in combination with DMC in human HT-29 colorectal cancer (CRC) cells. HT-29 CRC cells were treated with IC₅₀ dose of imatinib (6.60 μM), DMC (23.45 μM), and their combination (half dose of IC₅₀) for 24 h. The caspase-3 activity was estimated with colorimetric kit. The caspase-3 gene expression was evaluated by real-time PCR method. There was a significant up-regulation in caspase-3 enzyme activity and caspase-3 expression by imatinib and its half dose combination with DMC as compared to control. As a summary, the results of this study strongly suggest that half dose combination of imatinib with DMC induced apoptosis as potent as full dose imatinib in human HT-29 CRC cells, while minimizing undesired side effects related to imatinib mono-therapy. This study also pointed towards possible caspase-dependent actions of imatinib and DMC.

Keywords: Imatinib; Dimethyl-celecoxib; Apoptosis; Gene expression; Colorectal cancer cell line.

INTRODUCTION

Colorectal cancer is one of the major causes of morbidity and mortality worldwide and chronic inflammation is accepted to have a significant effect in the promotion and progression of this disease (1). It is well-known that chemotherapy plays significant role in the treatment of colorectal cancer depending on the stage of the disease. The most common chemotherapy drugs using for this cancer include capecitabine (2), fluorouracil (3), irinotecan (4), oxaliplatin (5). Imatinib is a potentially novel drug for the treatment of adenoma formation and cancer progression in patients predisposed to develop colorectal cancer (6). This agent as a protein tyrosine kinase inhibitor is appeared to have apoptotic and anti-proliferative actions in several cancers including colorectal cancer (7,8). HT-29 cell line showed responsiveness

to imatinib by means of a reduced proliferation or induction of apoptosis (9). This drug often has side effects like nausea, vomiting, diarrhoea, neutropenia, and anemia (10). Thus, imatinib is not usually considered a main medicine and is more frequently used in combination with other drugs like bevacizumab and cyclophosphamide as a therapy for advanced colorectal cancer (11).

Nonsteroidal anti-inflammatory drugs (NSAIDs) are another option which have been used to diminish the toxicity of conventional chemotherapeutic drugs (12).

Of course, the use of NSAID for example celecoxib, rofecoxib, valdecoxib, and parecoxib are associated with increased side effects due to inhibition of cyclooxygenase-2 (COX-2) (13-15).

*Corresponding author: F. Kheradmand
Tel: 0098 4432770397; Fax: 0098 4432780801
Email: f_kheradmand@umsu.ac.ir

2,5-dimethyl-celecoxib (DMC) as a close derivative of celecoxib is able to faithfully mimic all of celecoxib's numerous anti-cancer effects that have been examined so far, despite its inability to inhibit COX-2 (16,17). DMC has been reported to show *in vitro* anti-tumor efficacy as strongly as celecoxib and both drugs are potent inducers of apoptosis (18,19). This is an assumption that DMC can be a good choice for cancer treatment in the future.

In this study, we have investigated the combination effects of half dose imatinib and DMC on HT-29 human colorectal cancer cell line. According to our knowledge, this study is the first to investigate the combinatory anticancer effects of imatinib and DMC for colorectal cancer treatment.

MATERIALS AND METHODS

Cell culture and drug treatment

The human CRC cell line HT-29 (purchased from Iranian Biological Resource Center, Tehran, Iran) was routinely grown in Dulbecco's Modified Eagles Medium (DMEM) (ATOCEL, Australia) supplemented with 10% fetal bovine serum (FBS) (ATOCEL, Australia) and penicillin / streptomycin (ATOCEL, Australia). Imatinib (Cayman Chemical Co., USA) and DMC (Sigma-Aldrich Co., USA) were freshly dissolved in dimethyl sulfoxide DMSO (the drug vehicle) to yield a stock solution of 20 mM. The concentration of drugs was selected on the basis of their IC₅₀ values obtained by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay in our previous work which were 6.60 μM for imatinib and 23.45 μM for DMC (20). Briefly, 100 μL medium including 5 × 10³ HT-29 cells were seeded in each well of a 96-well plate. At 24 h after seeding, the cells were washed with phosphate-buffered saline (PBS) and treated with 7 μM imatinib, 24 μM DMC alone and their half dose combinations; imatinib (3.5 μM) + DMC (12 μM). An equal volume of DMSO was added to the control wells.

Measurement of caspase-3 enzyme activity

The caspase-3 colorimetric assay kit (Abnova, Taiwan) was used to determine the caspase-3 enzyme activity of the cells. Briefly, after 24 h treatment of HT-29 cells with

mentioned drugs, the medium was removed and cells were collected by centrifugation at 14,000 rpm for 5 min. Then, 50 μL of cell lysis buffer (10 mM Tris-HCl pH 7.6, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100) was added to the cells. After the lysis, cells were kept on ice for 10 min and centrifuged at 10,000 Rcf for 1 min. Protein concentration was determined with the Bradford method (21). Samples were dyed with coomassie brilliant blue G-250 (Serva Electrophoresis GmbH, Heidelberg, Germany), and the measurements were performed at 595 nm using a BioTek spectrophotometer (USA). Into each well of a 24-well plate, 50 μg proteins were diluted by adding cell lysis buffer. 50 μL 2× reaction buffer (containing 10 mM dithiothreitol) was added to each well then 5 μL DEVD-pNA 4 mM substrate (200 μM final concentration) was added, and the plates were incubated at 37 °C for 2 h. The sample plate was read at 400 or 405 nm with a microtiter plate reader.

RNA extraction and cDNA synthesis

For extraction of total RNA about 5 × 10⁵ HT-29 treated cells were harvested in PBS and centrifuged at 12000 rpm for 15 min. Total cellular RNA was isolated from cells using the total RNX-Plus solution kit (CinnaGen Co., Iran) according to the manufacturer's protocol. The purity of the extracted RNA was confirmed by measuring the ratio of optical density at 260 nm to that at 280 nm and its integrity was examined by electrophoresis on agarose gel. Complementary DNA (cDNA) was prepared from 2 μg of total RNA using the 2-steps RT-PCR kit with M-MuLV RT/Taq DNA polymerase and RTPL12-100app (Vivantis, Malaysia) according to the manufacturer's instructions. We designed caspase-3 specific and β-actin primers (as an invariant housekeeping gene). The sequences of the primers and the respective conditions used are shown in Table 1. For amplification by PCR, cDNA was subjected to 30 cycles of denaturation for 30 s at 95 °C, annealing for 30 s at 59 °C, and extension for 30 s at 72 °C. The RT-PCR products were then visualized by ethidium bromide after electrophoresis on 2% agarose gel. Also, the synthesized cDNA was directly used as template for real time RT-PCR using Bio-Rad iQ5 cyclor sequence detection system (Bio-Rad Laboratories Inc.).

Table 1. Sequences of primers used to evaluate expression of β -actin and caspase-3 genes in HT-29 cell line.

Target gene	Primer sequence	Product size (bp)	T (°C)
β -actin-forward	5'-CTGGAACGGTGAAGGTGACA-3'	161	59.3
Reverse	5'-TGGGGTGGCTTTTAGGATGG-3'		
Caspase-3-forward	5'-AGAAGTGGACTGTGGCATTGAG-3'	191	59.9
Reverse	5'-GCTTGTCCGCATACTGTTTCAG-3'		




Fig. 1. Effect of (A) imatinib and (B) DMC on HT-29 cell apoptosis. HT-29 colorectal cancer cells were treated with 4, 6, and 8 μ M of imatinib or 20, 40, and 60 μ M of dimethyl celecoxib (DMC) for 24 h. Apoptosis induction was measured by caspase-3 assay compared to untreated cells (control). The data are depicted as means \pm SEM. Asterisks indicate sample that is significantly different compared to other samples using analysis of variance. (* P < 0.05).

Real time PCR of caspase-3 mRNA

Real time RT-PCR was performed by using AccuPower[®]2 \times GreenStar qPCR master mix(Bioneer, South Korea) in a total volume of 25 μ L according to the manufacturer's instructions. The reactions were prepared in a 96-well optical plate for 10 min at 95 °C followed by 40 cycles of 20 s at 95 °C and 45 s at 59 °C. In addition, a no-template control was used to test the potential contamination and primer dimer formation. The relative expression of each mRNA was calculated using the $2^{-\Delta\Delta C_t}$ method, where C_t is the threshold cycle (22). Relative expression levels of mRNA were normalized to β -actin and analyzed for statistical significance with one-way analysis of variance using SPSS 16 statistical analysis software.

Statistical analysis

The results were expressed as the mean \pm SEM for at least three separate experiments for each treatment. Statistical significance of differences between mean values was analyzed by one way ANOVA followed by Tukey's HSD post-hoc test using SPSS 16 statistical

analysis software. The level of significant difference was set at P < 0.05. The fold differences of gene expression normalized to the control was presented graphically in the form of histograms, using Microsoft Excel computer program.

RESULTS

Caspase-3 activity of HT-29 cells treated with imatinib, DMC, and their combinations

As shown in Figs. 1A and 1B, imatinib and DMC produced dose-dependent caspase-3 activity induction in HT-29 cell lines. Based on our results, 4 μ M imatinib showed insignificant difference compared to control treatment. However, treatment at 6 and 8 μ M increased caspase-3 activity significantly (P < 0.01), (Fig. 1A). Treatment with 20, 40, and 60 μ M DMC for 24 h showed significant difference compared to control treatment (Fig. 1B). Treatment with 6 μ M imatinib had no significant difference in comparison to 8 μ M imatinib and also there was no significant difference between DMC-treated groups (40 and 60 μ M). Therefore, to study the combined

effects of these drugs, we used lower effective doses of them (half dose of IC₅₀ values that previously approved with MTT assay (20)).

The most potent apoptotic effects in combination treatment were observed at a concentration of 3.5 μM imatinib and 12 μM DMC which was statistically significant compared to control (Fig. 2). Treatment with imatinib (3.5 μM) and DMC (12 μM) for 24 h increased apoptosis to 76% versus control ($P < 0.001$). The combined treatment showed more apoptosis induction than each of the drugs alone compared to control (50% for 7 μM imatinib and 38% for 24 μM DMC).

Effect of imatinib in combination with DMC on caspase-3 gene expression

Based on the preliminary results, a combination of 3.5 μM imatinib and 12 μM

DMC were used for complementary tests. According to real time RT-PCR results, there was an approximately 2-fold and 1-fold increase of caspase-3 mRNA as a result of 7 μM imatinib ($P = 0.05$) and 24 μM of DMC ($P < 0.05$) treatment compared to the vehicle-treated control group in HT-29 cells, respectively. However, the combined treatment with 3.5 μM imatinib and 12 μM DMC noticeably increased the level of caspase-3 mRNA in HT-29 cells (3 fold) as compared to the untreated control group ($P < 0.001$) (Fig. 3). These results indicate that imatinib increased caspase-3 mRNA expression more effectively when combined with DMC.

Results of present study also pointed towards possible caspase-dependent actions of imatinib and DMC.




Fig. 2. Effect of imatinib in combination with DMC on HT-29 cell apoptosis. HT-29 CRC cells were treated for 24 h with 7 μM of imatinib or 24 μM of dimethyl celecoxib (DMC) alone and half dose of imatinib (3.5 μM) plus DMC (12 μM) combination. Apoptosis induction was measured by caspase-3 assay compared to untreated cells (control) ($P < 0.05$), * $P < 0.05$ versus control.




Fig. 3. Real-time quantitative RT-PCR analysis to determine the effects of imatinib (IM) (7 μM), dimethyl celecoxib (DMC) (24 μM) alone and in combination with each other (IM 3.5 μM + DMC 12 μM) on caspase-3 mRNA levels with β-actin as the internal control. Vertical bars indicate the mean fold changes ± SEM for three independent experiments in each treatment group. Imatinib and its half dose combination with DMC significantly increased the expression of caspase-3 mRNA compared to untreated HT-29 cells for 24 h * $P < 0.05$ versus control.

DISCUSSION

In the current study, we observed that imatinib and its combination with DMC significantly increased caspase-3 enzyme activity. Apoptosis effects of imatinib in combination with DMC associated with increase in caspase-3 mRNA levels in HT-29 colorectal cancer cells. Inhibition of HT-29 cell proliferation and apoptosis induction by imatinib has been shown in previous studies (8,9). Also DMC's anti-proliferative and apoptotic effects have been shown in tumor cells *in-vitro* and *in-vivo* (23). We didn't find any study about the effect of imatinib in combination with DMC on HT-29 colorectal cancer cells. Stahtea, *et al.* proved that imatinib with 5-Fluorouracil combination significantly enhances the growth inhibition of the highly tumorigenic HT-29 cells (9). Accordingly Abdel-Aziz, *et al.* showed that selenite-imatinib combination was more effective than single drugs in increasing caspase-3 activity, apoptosis induction and reducing bcl-2 expression in HCT116 cells (7). Shi, *et al.* showed imatinib with tetrandrine combination obvious synergistic effect, probably due to up-regulation of caspase-3 mRNA and protein expressions, and down-regulation of bcl-2 mRNA and protein expressions (24). Baran, *et al.* also showed apoptosis induction through loss of mitochondrial membrane potential and increases in caspase-3 enzyme activity by fludarabine and imatinib combination in human K562 chronic myeloid leukemia cells (25).

Combination therapy seems to have the potential to be more effective than single agent imatinib in the prevention of imatinib resistance (26,27) and recurrent dose interruption (28,29) which have been shown by imatinib monotherapy. Besides the use of appropriate combination of these drugs might be effective in reducing the side effects of imatinib (30). In the present study, we have shown comparable effect of half dose combination with full dose monotherapy. According to our findings, imatinib alone and in combination with DMC significantly up-regulated caspase-3 gene expression and activity. Then the enhanced potency of DMC

in our study seems to be mediated, at least in part, by caspase-3-dependent mechanism. It is especially noteworthy that DMC showed augmenting effects with imatinib on apoptosis in HT-29 cells at low concentration of DMC and imatinib (half dose of IC₅₀).

Our previous study also showed that imatinib-celecoxib combination effectiveness in HT-29 colorectal cancer cells (31). DMC mimics all of celecoxib's numerous anti-cancer effects despite its inability to inhibit COX-2 (16). In the present study, imatinib in combination with DMC (half dose of IC₅₀) showed remarkable potent effects on HT-29 colorectal cancer cells which was more noticeable than imatinib in combination with celecoxib (half dose of IC₅₀). DMC (in low dose alone) and especially in combination with imatinib might not cause the serious side effects that recently developed with the prolonged use of coxibs such as celecoxib that inhibit COX-2 (13,14). The increased effectiveness of imatinib in combination with DMC should be considered as advantages in clinical practice. In contrast to celecoxib, DMC has not yet been studied in humans and evaluation of the *in vitro* mechanism should be followed by appropriate preclinical assays.

CONCLUSION

We conclude that imatinib and especially its combination with DMC has a role in apoptosis induction through caspase-3 pathway in colorectal cancer cells which was confirmed by up-regulation of the caspase-3 expression. Therefore, these findings provide further perceptions to the possible use of DMC in combination with other drugs without the undesired side effects related to mono-targeting, although results require further investigation especially before using this combination in clinical practice.

ACKNOWLEDGEMENTS

The authors would like to thank members of the Cellular and Molecular Research Center of Urmia University of Medical Sciences, Urmia, Iran.

REFERENCES

- Danese S, Mantovani A. Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer. *Oncogene*. 2010;29(23):3313-3323.
- Twelves C, Wong A, Nowacki MP, Abt M, Burris H, Carrato A, et al. Capecitabine as adjuvant treatment for stage III colon cancer. *N Engl J Med*. 2005;352(26):2696-2704.
- Nita ME, Nagawa H, Tominaga O, Tsuno N, Fujii S, Sasaki S, et al. 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins. *Br J Cancer*. 1998;78(8):986-992.
- Fuchs C, Mitchell EP, Hoff PM. Irinotecan in the treatment of colorectal cancer. *Cancer Treat Rev*. 2006;32(7):491-503.
- Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. *J Clin Oncol*. 2009;27(19):3109-3116.
- Kundu P, Genander M, Straat K, Classon J, Ridgway RA, Tan EH, et al. An EphB-Abl signaling pathway is associated with intestinal tumor initiation and growth. *Sci Transl Med*. 2015;7(281):281ra44.
- Abdel-Aziz AK, Azab SS, Youssef SS, El-Sayed AM, El-Demerdash E, Shouman S. Modulation of imatinib cytotoxicity by selenite in HCT116 colorectal cancer cells. *Basic Clin Pharmacol Toxicol*. 2015;116(1):37-46.
- Attoub S, Rivat C, Rodrigues S, Van Bocxlaer S, Bedin M, Bruyneel E, et al. The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy. *Cancer Res*. 2002;62(17):4879-4883.
- Stahtea XN, Roussidis AE, Kanakis I, Tzanakakis GN, Chalkiadakis G, Mavroudis D, et al. Imatinib inhibits colorectal cancer cell growth and suppresses stromal-induced growth stimulation, MT1-MMP expression and pro-MMP2 activation. *Int J Cancer*. 2007;121(12):2808-2814.
- Tamasciaro I, Ramnarayanan J. Targeted treatment of chronic myeloid leukemia: role of imatinib. *Oncol Targets Ther*. 2009;2:63-71.
- Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, et al. A phase I trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. *Br J Cancer*. 2013;109(7):1725-1734.
- Sabharwal A, Kerr D. Chemotherapy for colorectal cancer in the metastatic and adjuvant setting: past, present and future. *Expert Rev Anticancer Ther*. 2007;7(4):477-487.
- Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. *N Engl J Med*. 2005;352(11):1092-1102.
- Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoelt A, Parlow JL, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. *N Engl J Med*. 2005;352(11):1081-1091.
- Sadeghi-Aliabadi H, Aliasgharluo M, Fattahi A, Mirian M, Ghanadian M. *In vitro* cytotoxic evaluation of some synthesized COX-2 inhibitor derivatives against a panel of human cancer cell lines. *Res Pharm Sci*. 2013;8(4):298-303.
- Backhus LM, Petasis NA, Uddin J, Schonthal AH, Bart RD, Lin Y, et al. Dimethyl celecoxib as a novel non-cyclooxygenase 2 therapy in the treatment of non-small cell lung cancer. *J Thorac Cardiovasc Surg*. 2005;130(5):1406-1412.
- Virrey JJ, Liu Z, Cho HY, Kardosh A, Golden EB, Louie SG, et al. Antiangiogenic activities of 2,5-dimethyl-celecoxib on the tumor vasculature. *Mol Cancer Ther*. 2010;9(3):631-641.
- Fan X, Takahashi-Yanaga F, Morimoto S, Zhan DY, Igawa K, Tomooka K, et al. Celecoxib and 2,5-dimethyl-celecoxib prevent cardiac remodeling inhibiting Akt-mediated signal transduction in an inherited dilated cardiomyopathy mouse model. *J Pharmacol Exp Ther*. 2011;338(1):2-11.
- Pyrko P, Soriano N, Kardosh A, Liu YT, Uddin J, Petasis NA, et al. Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells *in vitro* and *in vivo*. *Mol Cancer*. 2006;5:19.
- Nikanfar S, Atari-hajipirloo S, Heydari A, Kheradmand F. Combination of imatinib and celecoxib, synergistically inhibit cell proliferation in colon cancer cells. Poster No. 68. 5th International congress on cell membranes and oxidative stress: focus on calcium signaling and TRP channels. 2014;6(1):361.
- Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem*. 1976;72(1-2):248-254.
- Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods*. 2001;25(4):402-408.
- Kardosh A, Soriano N, Liu YT, Uddin J, Petasis NA, Hofman FM, et al. Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib. *Blood*. 2005;106(13):4330-4338.
- Shi DX, Ma LM, Lu YJ, Bai B. [Apoptosis-inducing effect of tetrandrine and imatinib on K562/G01 cells and its related mechanism]. *Zhongguo Shi Yan Xue Ye Xue Za Zhi*. 2014;22(3):723-728.
- Baran Y, Oztekin C, Bassoy EY. Combination of fludarabine and imatinib induces apoptosis synergistically through loss of mitochondrial membrane potential and increases in caspase-3 enzyme activity in human K562 chronic myeloid leukemia cells. *Cancer Invest*. 2010;28(6):623-628.
- Hsieh YY, Yen CC, Yeh CN, Tzen CY, Liu JH, Lee HJ, et al. Effective salvage therapy of imatinib-

- resistant gastrointestinal stromal tumor with combination of imatinib and pegylated liposomal doxorubicin. *J Chin Med Assoc.* 2011;74(6):272-274.
27. Schoffski P, Reichardt P, Blay JY, Dumez H, Morgan JA, Ray-Coquard I, *et al.* A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. *Ann Oncol.* 2010;21(10):1990-1998.
 28. Gajiwala KS, Wu JC, Christensen J, Deshmukh GD, Diehl W, DiNitto JP, *et al.* KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. *Proc Natl Acad Sci U S A.* 2009;106(5):1542-1547.
 29. Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, *et al.* Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. *J Clin Oncol.* 2006;24(29):4764-4774.
 30. Gross DJ, Munter G, Bitan M, Siegal T, Gabizon A, Weitzen R, *et al.* The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. *Endocr Relat Cancer.* 2006;13(2):535-540.
 31. Atari-Hajipirloo S, Nikanfar S, Heydari A, Noori F, Kheradmand F. The effect of celecoxib and its combination with imatinib on human HT-29 colorectal cancer cells: involvement of COX-2, caspase-3, VEGF and NF-kappaB genes expression. *Cell Mol Biol(Noisy-le-grand).* 2016;62(2):68-74.